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ABSTRACT
Allogeneic donor T cells in bone marrow transplantation (BMT) can contribute to beneficial graft-versus-
leukemia (GVL) effects but can also cause detrimental graft-versus-host disease (GVHD). A successful method
for the ex vivo treatment of donor T cells to limit their GVHD potential while retaining GVL activity would
have broad clinical applications for patients undergoing allogeneic hematopoietic cell transplantation for
malignant diseases. We hypothesized that donor lymphocyte infusions treated with fludarabine, an immuno-
suppressive nucleoside analog, would have reduced GVHD potential in a fully major histocompatibility
complex–mismatched C57BL/6 3 B10.BR mouse BMT model. Recipients of fludarabine-treated donor
lymphocyte infusions (F-DLI) had significantly reduced GVHD mortality, reduced histopathologic evidence of
GVHD, and lower inflammatory serum cytokine levels than recipients of untreated DLI. Combined compar-
isons of GVHD incidence and donor-derived hematopoietic chimerism indicated that F-DLI had a therapeutic
index superior to that of untreated DLI. Furthermore, adoptive immunotherapy of lymphoblastic lymphoma
using F-DLI in the C57BL/63 B10.BR model demonstrated a broad therapeutic index with markedly reduced
GVHD activity and preservation of GVL activity compared with untreated allogeneic T cells. Fludarabine
exposure markedly reduced the CD4CD44low-naive donor T-cell population within 48 hours of transplan-
tation and altered the relative representation of cytokine-producing CD4 T cells, consistent with T-helper
type 2 polarization. However, proliferation of fludarabine-treated T cells in allogeneic recipient spleens was
equivalent to that of untreated T cells. The results suggest that fludarabine reduces the GVHD potential of
donor lymphocytes through effects on a CD4CD44low T-cell population, with less effect on alloreactive T
cells and CD4CD44high memory T cells that are able to mediate GVL effects. Thus, F-DLI represents a novel
method of immune modulation that may be useful to enhance immune reconstitution among allograft
recipients with reduced risk of GVHD while retaining beneficial GVL effects.
© 2003 American Society for Blood and Marrow Transplantation
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● ● ●NTRODUCTION
Graft-versus-host disease (GVHD) initiated by
onor T cells is a major complication of allogeneic
one marrow transplantation (BMT). Because alloge-
eic T cells also provide beneﬁcial graft-versus-leuke-
ia effects (GVL) and antimicrobial immunity, there
s great interest in developing a method for separating
hese 2 linked activities. The ideal graft would include16apid engraftment and donor T cells capable of con-
ributing to posttransplantation immune reconstitu-
ion and GVL effects without causing GVHD. We
ave previously demonstrated that irradiated donor T
ells have the ability to facilitate engraftment of allo-
eneic bone marrow (BM) cells without causing
VHD in the recipients [1]. This approach has been
pplied in clinical trials, with promising results [2], butGraft-versus-host disease Naive T cel
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aufﬁcient donor hematopoietic progenitor cells for it may have limited clinical application because infu-
sions of large numbers of irradiated splenocytes (SP)
result in persistent mixed chimerism in a murine
model and do not contribute to long-term immune
reconstitution [1]. Recipients of allogeneic transplants
with persistent mixed (host donor) chimerism in the
T-cell compartment have less of the GVL effect than
recipients that achieve full donor chimerism [3].
To achieve more consistent donor chimerism and
better survival among recipients of allogeneic T cells,
we have evaluated the use of an immunosuppressive
agent, ﬂudarabine, as an alternative method of treat-
ing T cells to limit their potential for GVHD while
preserving GVL activity. Fludarabine (9--d-arabino-
syl-2-ﬂuoroadenine) is an adenine nucleoside analog
that inhibits DNA synthesis when incorporated into a
replicating chain [4,5]. Fludarabine also inhibits the
proliferative responses of human CD4 and CD8 T
cells to mitogen and alloantigen [6] and has potent
immunosuppressive effects, including profound deple-
tion of CD4 T cells [7] and induction of apoptosis in
resting lymphocytes [8]. Fludarabine is known to in-
hibit STAT1 signaling in resting T cells, leading to
decreased proliferation in response to cytokine activa-
tion [9]. We hypothesized that ﬂudarabine pretreat-
ment of donor T cells would render them susceptible
to activation-induced cell death, thus selectively elim-
inating antigen-speciﬁc T cells responding to alloan-
tigen in the host. This would potentially spare donor
T cells that could contribute to reconstitution of the
naive T-cell repertoire.
Results of major histocompatibility complex (MH-
C)–mismatched allogeneic murine transplant experi-
ments demonstrate that adoptive immunotherapy
with ﬂudarabine-treated donor lymphocytes indeed
resulted in signiﬁcantly reduced GVHD morbidity
and mortality compared with untreated donor lym-
phocytes while preserving graft-facilitating effects. It
is important to note that GVL activity against a trans-
planted T-cell lymphoma cell line was retained. How-
ever, ﬂudarabine pre-exposure did not reduce the al-
loreactivity of T cells in both in vitro and short-term
in vivo transfer experiments. Contrary to our original
hypothesis, the major immunomodulatory effect of
ﬂudarabine treatment on donor lymphocyte infusions
(DLI) seemed to involve selective reduction of a donor
CD4CD44low-naive T-cell population and alteration
of the T-cell cytokine secretion proﬁle consistent with
T-helper type 2 (Th-2) polarization. These effects did
not change the proliferative response of ﬂudarabine-
treated donor T cells in allogeneic recipient spleens,
suggesting that donor CD4CD44low cells play an
important role in GVHD progression, independent of
donor T-cell expansion. Thus, ﬂudarabine-treated
lymphocytes may represent a novel method for reduc-
ing the GVHD risk of DLI in allogeneic BMT while
preserving therapeutic GVL effects.
MATERIALS AND METHODS
Animals
Male B10.BR mice (H-2k, CD45.2, and Thy1.2)
and a congenic strain of C57BL/6 mice (H-2b,
CD45.1, and Thy1.2), aged 8 to 10 weeks, were pur-
chased from Jackson Laboratories (Bar Harbor, ME).
A Thy1.1 congenic strain of C57BL/6 (H-2b, CD45.2,
and Thy1.1) was obtained from Miriam Lieberman
(Stanford University, CA), and a third congenic strain
of C57BL/6 (H-2b, CD45.1, and Thy1.1) was bred
and maintained at Emory University. Some experi-
ments used DBA/2 (H-2d), BALB/c scid/scid (H-2d),
and 2CTCR transgenic mice (C57BL/6 background)
with T cells allospeciﬁc against H-2d [10], purchased
from Jackson Laboratories. Mice were housed in mi-
croisolator cages in the Emory University Animal
Care Facility, with acidiﬁed water and standard chow
available at all times. Animal handling and experimen-
tal procedures were in concordance with the Guide for
the Care and Use of Laboratory Animals (National Acad-
emy Press, Washington, DC, 1996) and approved by
the Emory University Institutional Animal Care and
Use Committee.
T Cell–Depleted BM
Femora and tibiae were removed from C57BL/6
(H-2b, CD45.1, and Thy1.1) mice, and BM cells were
expelled by ﬂushing sterile phosphate-buffered saline
(PBS) containing 1% heat-inactivated fetal bovine se-
rum (FBS) through the shaft. CD3 T cells were
depleted by using immunomagnetic separation tech-
niques (MACS, Miltenyi Biotech GmbH, Bergisch-
Gladbach, Germany). T cell–depleted (TCD) BM
was analyzed by ﬂow cytometry and routinely con-
tained 0.5% residual T cells.
Fludarabine-Treated SP
Spleens from C57BL/6 (H-2b, CD45.1, and
Thy1.2 or H-2b, CD45.2, and Thy1.1) mice were
perfused with sterile PBS/FBS. Spleen contents were
gently removed from the capsule, washed, and
strained to obtain a single-cell suspension. SP (10 
106/mL) were then incubated in complete media
(RPMI supplemented with 10% heat-inactivated FBS,
50 M 2-mercaptoethanol, 100 U/mL penicillin, 100
g/mL streptomycin, 292 g/mL l-glutamine, 1 mM
sodium pyruvate, and nonessential amino acids [Bio-
whittaker, Walkersville, MD]). Fludarabine (Berlex
Laboratories, Richmond, CA) was added to a ﬁnal
concentration of 20 g/mL; control SP were cultured
without ﬂudarabine. Cultures were maintained at
37°C in a 5% CO2 incubator for 24 hours. Overall
viability was assessed by counting ethidium bromide/
acridine orange–stained cells under ﬂuorescence mi-
croscopy. The representation of T- and B-cell popu-
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lations among surviving SP was determined by ﬂow
cytometric analyses by using ﬂuorochrome-conju-
gated antibodies against mouse CD3, CD4, CD8, and
CD19. Propidium iodide staining was used to exclude
dead cells from the analysis. In all subsequent trans-
plant and in vitro experiments, the number of ﬂudara-
bine-treated or -untreated SP used was based on the
viable cell count. SP were washed and resuspended to
prepare DLI and ﬂudarabine-treated DLI (F-DLI).
Conditioning and Transplantation
B10.BR recipient mice were irradiated (2  5.5
Gy, 3-hour interval) 1 day before transplantation by
using a cesium 137 source at a rate of 1.24 Gy/min.
Irradiated mice were given drinking water containing
antibiotics (1.1 mg/mL neomycin sulfate and 1000
U/mL polymixin sulfate) for 4 weeks after BMT.
Donor cell infusions were prepared in 0.2 mL of
Hanks balanced salt solution/1% FBS per recipient.
For GVHD and graft facilitation experiments, 1 106
TCD-BM cells were administered alone or mixed
with DLI or F-DLI. The number of DLI or F-DLI
transplanted varied for dose-escalation studies. Some
experiments also used mixtures of TCD-BM, B cell–
depleted (BCD) SP (MACS [immunomagnetic sepa-
ration techniques] depletion of CD19 cells resulted
in approximately 3% residual B cells), and irradiated
(7.5 Gy) SP. All transplants were administered via tail
vein injection.
Assessment of GVHD in Transplant Recipients
Recipient mice were monitored daily for survival;
moribund animals were killed and their deaths re-
corded. Animals were weighed twice a week for the
ﬁrst month after transplantation and then weekly until
termination of survival experiments. For GVHD as-
sessment experiments, groups of 3 to 8 mice were
killed at predetermined time points for analysis of
serum cytokine levels, donor cell proliferation in re-
cipient spleen (see below), and histologic examination
of liver and colon sections. Tissues were removed,
ﬁxed in 10% buffered formalin, and embedded in
parafﬁn, and sections were stained with hematoxylin
and eosin for histologic examination. Slides were
coded and scored for evidence of GVHD (grade 0-4)
without knowledge of treatment conditions by a
trained pathologist (D.L.J.) by using previously re-
ported criteria [1,11]. Histologic evidence of GVHD
included inﬁltration of lymphocytes in the periportal
regions of the liver and apoptotic cells in the intestinal
epithelium of the colon, particularly in the crypts,
along with foci of epithelial ulceration.
Measurement of Serum Cytokine
Levels/Enzyme-Linked Immunosorbent Assay
Recipient mice were anesthetized by isoﬂurane
inhalation, and peripheral blood was collected by
retro-orbital bleeding into Microtainer serum separa-
tion tubes (Beckton Dickinson, Franklin Lakes, NJ).
Mice were killed immediately after bleeding. Serum
was obtained and stored frozen at 80°C until use.
Tumor necrosis factor (TNF)- and interferon
(IFN)- levels were assayed by using OptEIA enzyme-
linked immunosorbent assay sets (Pharmingen, San
Diego, CA), and reaction dishes were analyzed with a
SpectraMax 340PC spectrophotometer (Molecular
Devices, Sunnyvale, CA). All samples were assayed in
duplicate wells.
Analysis of Hematopoietic Chimerism
Peripheral blood (0.2 mL) was collected by tail
vein nick at 1 to 4 months after BMT. Red blood cells
were lysed by brief treatment with an ammonium
chloride solution. Leukocytes were then washed and
resuspended in Hanks balanced salt solution contain-
ing 2 mM EDTA and 3% FBS. Donor and host-
derived leukocytes and T cells were distinguished by
ﬂow cytometric analysis by using ﬂuorochrome-con-
jugated monoclonal antibodies speciﬁc for H-2b and
H-2k MHC, as well as speciﬁc leukocyte markers
(CD3, CD4, CD8, Thy1.1, Thy1.2, CD45.1, and
CD45.2; Pharmingen). Similar procedures were used
to determine the donor-derived T- and B-cell content
of recipient spleens.
Leukemic Cell Line and GVL Transplant
Experiments
A radiation-induced splenic lymphoma cell line
from the B10.BR mouse, LBRM [12] was obtained
from the American Type Culture Collection (Rock-
ville, MD) and used here as a transplantable leukemic
tumor in GVL experiments. B10.BR recipient mice
were irradiated on day2, administered 3 106 (	10
times the median lethal dose [LD50]) LBRM tumor
cells via tail vein injection on day1, and transplanted
with allogeneic TCD-BM and DLI on day 0. Depend-
ing on the experimental protocol, additional infusions
of DLI were administered on a weekly basis as indi-
cated.
Proliferative Response to Alloantigen (Mixed
Lymphocyte Reaction) and Mitogen
A total of 4  106 cells per milliliter of responder
cells (SP obtained from C57BL/6 3 B10.BR trans-
plant recipients or fresh B10.BR SP) were cocultured
with 2  106 irradiated (25 Gy) stimulator cells per
milliliter (C57.BL6, B10.BR, or DBA/2) or 10 g/mL
concanavalin A in complete media with 10 U/mL
interleukin (IL)-2 (Chiron Corporation, Emeryville,
CA) and 10 ng/mL IL-7 (PeproTech Inc., Rocky Hill,
NJ) in triplicate wells of a 96-well plate. Proliferation
was monitored by measuring DNA thymidine incor-
poration. Cultures were pulsed with 1 Ci per well of
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618
tritiated thymidine (NEN Life Sciences, Boston, MA)
on day 6, harvested onto ﬁltermats by using a Tomtec
Harvester (Hamden, CT) on day 7, and read on a
MicroBeta TriLux counter (PerkinElmer, Wallac
Inc., Gaithersburg, MD).
Limiting Dilution Analysis
The frequency of alloreactive cells was measured
by using a limiting dilution assay [13]. Brieﬂy, 20,000
C57BL/6 responder cells (untreated or ﬂudarabine-
treated SP) were 3-fold serially diluted in 96-well
plates with 12 replicate wells per dilution. Then
10,000 irradiated B10.BR stimulator cells were added
to each well in a combined total volume of 200 L of
complete media. After 7 days, the proliferation of
responder cells was measured by using tritiated thy-
midine incorporation. The number of responder cells
was plotted versus the natural logarithm of the per-
centage of negative wells (ie, wells with counts per
minute readings less than media control [average  3
SD]). The reciprocal of the slope of the regression line
yielded the frequency of alloreactive T cells.
5-[and-6]-Carboxyfluorescein Diacetate,
Succinimidyl Esther In Vivo Proliferation Analysis
5-[and-6]-Carboxyﬂuorescein diacetate, succin-
imidyl esther (CFSE; Molecular Probes, Eugene, OR)
staining was performed by using a slight modiﬁcation
of methods outlined by Lyons [14]. After 24-hour
culture in standard or ﬂudarabine-containing media,
donor SP (C57BL/6 alone or combined with trans-
genic 2CTCR T cells [10]) were washed and resus-
pended at 5  107/mL in PBS containing 0.5% FCS.
CFSE was added to a ﬁnal concentration of 3 M, and
cells were incubated 10 minutes at 37°C and then
washed twice. Then 3  107 CFSE-labeled cells were
administered to irradiated (3 Gy) BALB/c (H-2d) scid/
scid mice, unirradiated F1(C57BL/6  B10.BR), or
irradiated (11 Gy) B10.BR recipient mice via tail vein
injection. Recipient mice were killed 1 to 4 days after
transplantation, and SP harvested for ﬂow cytometric
analysis of donor cell proliferation. R-Phycoerythrin
(PE), PerCP, or allophycocyanin (APC) conjugated
antibodies against T-cell surface markers were used
for simultaneous analysis of T-cell subsets.
Intracellular Cytokine Analysis
SP were removed from 24-hour culture with or
without ﬂudarabine, washed, and placed in fresh me-
dia for 16 hours. Phorbol 12-myristate 13-acetate
(PMA)/ionomycin and a protein transport inhibitor
(GolgiStop; Pharmingen) were then added for an ad-
ditional 5 hours by using conditions speciﬁed by the
supplier. Cells were assayed for simultaneous expres-
sion of T-cell phenotypic markers (CD4 or CD8,
CD44, and CD25) and intracellular cytokine produc-
tion (IL-2, IL-10, IFN-, or TNF-) by using appro-
priate ﬂuorochrome-conjugated monoclonal antibod-
ies, isotype controls, and Cytoﬁx/Cytoperm reagents
(Pharmingen). Labeled cells were analyzed by ﬂow
cytometry.
T-Cell Purification
Splenic T cells were puriﬁed with an immu-
nodepletion protocol similar to that speciﬁed for the
Miltenyi Pan T-Cell Isolation Kit to remove cells
expressing B220, Ter-119, DX5, and CD11b. T-cell
purity was determined with ﬂow cytometric analysis
for CD3 cells and was routinely shown to be 	97%.
Statistical Analysis
Kaplan-Meier analysis was used to analyze the
survival of the animals. The differences in survival
among different treatment groups were tested with
the Wilcoxon log-rank test [15]. The Student t test
was used to compare in vitro assay results obtained
with ﬂudarabine-treated versus -untreated cells and to
determine the signiﬁcance of blinded histologic scor-
ing results from recipients of ﬂudarabine-treated ver-
sus -untreated cells.
RESULTS
T Cells Are Relatively Resistant to Killing by
Fludarabine Compared with B Cells
Experiments were conducted to determine the
yield of viable SP after 24 hours of culture in media
containing graded doses of ﬂudarabine (0, 3, 10, 20, or
40 g/mL) and to characterize the GVHD potential
of treated SP in the C57BL/6 3 B10.BR transplant
model. Increasing loss of viability among cultured
cells was dose dependent up to 10 g/mL ﬂudarabine,
and a plateau was seen at higher ﬂudarabine doses
(data not shown). Cultures treated with 20 g/mL
ﬂudarabine for 24 hours had approximately 42% over-
all cell viability, whereas control cultures had approx-
imately 75% viability compared with the starting cell
population (Table 1). The viability of B cells after
Table 1. Cell Viability after 24 Hours of Culture with or without 20
g/mL Fludarabine
Cell
population
0 g/mL
Fludarabine (%)
20 g/mL
Fludarabine (%)
P
Value
All leukocytes 74.5  2.9 41.6  7.8 .008
CD4 T cells 84.3  4.6 69.0  9.9 .232
CD8 T cells 81.2  3.7 62.1  12.9 .204
B cells 67.7  0.5 30.5  4.1 .006
*Results show the percentages of T-cell and B-cell populations that
remained viable after the culture period. The data represent the
mean 
 SEM for 4 individual experiments. P values were cal-
culated with a 2-tailed t test.
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ﬂudarabine treatment was signiﬁcantly reduced com-
pared with control cultures. T-cell viability was also
lower after ﬂudarabine exposure versus control for
both the CD4 and CD8 populations, but these differ-
ences did not reach statistical signiﬁcance (Table 1).
Allogeneic transplant experiments demonstrated that
mice receiving TCD-BM plus SP treated with 20
g/mL ﬂudarabine had the most favorable 40-day
survival rate compared with groups receiving control
SP or SP treated with other doses of ﬂudarabine (data
not shown). Hence, this dose was selected for further
studies. Note that for all subsequent transplant and in
vitro experiments, the number of ﬂudarabine-treated
or -untreated SP used was based on the number of
viable cells in the culture after the incubation period.
Treatment of Allogeneic Lymphocytes with
Fludarabine Reduced GVHD and Facilitated
Engraftment in the MHC-Mismatched
C57BL/6 3 B10.BR Transplant Model
A dramatic improvement in survival was observed
among B10.BR mice transplanted with graded doses
of F-DLI in combination with 1  106 TCD-BM
from C57BL/6 donors, compared with recipients of
untreated DLI. In this model system, the dose of
TCD-BM is low enough that the absence of addi-
tional donor SP leads to approximately 50% mortality
from aplasia and graft rejection (Figure 1A), with
autologous reconstitution of host-type hematopoiesis
or mixed chimerism in surviving mice. Recipients of
10  106 viable F-DLI (containing 4.8  106 viable T
cells) had approximately 65% survival at 140 days after
transplantation (Figure 1B), compared with no long-
term survival among recipients of TCD-BM plus
10  106 untreated DLI (containing 3.8  106 viable
T cells; P  .0005; Figure 1A). Transplantation of
graded doses of F-DLI in combination with
TCD-BM resulted in higher overall survival at all
F-DLI cell doses tested versus untreated DLI, with
the LD50 for F-DLI not reached at a viable cell dose
of 10  106 donor cells. Because the major toxicity of
DLI is GVHD and the most direct manifestations of
GVHD are weight loss and mortality, the product of
the day 60 average weight of survivors (as percent-
age of weight at day 0) and the fraction surviving was
calculated as a survival score for each dose of viable T
cells transplanted (Figure 1C). Increasing numbers of
untreated DLI produced a steep decline in the score,
with greater than 3-fold more toxicity per viable trans-
planted T cell (the slope of the line) compared with
the GVHD activity of F-DLI (Figure 1C). The addi-
tion of DLI or F-DLI to the TCD-BM graft increased
the level of donor T-cell chimerism in surviving ani-
mals (Figure 1D) and produced full donor-derived
myeloid chimerism (not shown). The therapeutic in-
dex (deﬁned as the donor T-cell dose that was associ-
ated with a toxic effect [weight  survival score of 80]
divided by the dose of T cells that produced a bene-
ﬁcial effect [	5% of donor spleen-derived T cells in
the blood at day 60]) was 3-fold higher for F-DLI
(2.6  3.6  106/1.4  106) than for untreated DLI
(0.9  1.2  106/1.1  106). An additional study
showed that the survival difference between transplant
recipient groups was more pronounced when donor
SP were cultured with ﬂudarabine for 24 hours and
then in fresh media without ﬂudarabine for 24 hours,
versus 48 hours of untreated culture. For both groups,
DLI were prepared so that 3 106 viable T cells were
administered per recipient. The F-DLI group exhib-
ited 80% survival at 100 days after transplantation
(n  15), compared with rapid GVHD mortality after
transplantation with untreated SP (0% survival at day
15; n  11; data not shown).
B-Cell Depletion of Allogeneic Donor SP, or
Mixing Apoptotic or Dead Donor Cells with Live
Donor T Cells, Did Not Reduce GVHD Activity
Our initial hypothesis predicted that ﬂudarabine
pre-exposure would have an immunosuppressive ef-
fect on donor T cells, ultimately resulting in reduced
GVHD potential. Although the preceding experi-
ments demonstrated reduced GVHD with F-DLI, the
results also raised the possibility that effects on B cells
in the F-DLI may have contributed to GVHD reduc-
tion [16] or, alternatively, that the large dead-cell
population infused with F-DLI may have provided a
GVHD-mitigating effect [17]. To address these ques-
tions, B10.BR mice were transplanted with C57BL/6
TCD-BM combined with untreated or ﬂudarabine-
treated B-cell–depleted SP (BCD-SP) or a mixture of
BCD-SP and irradiated (25 Gy) SP. BCD-SP was
prepared so that 2.2  106 viable T cells (untreated or
ﬂudarabine treated) were administered per recipient.
The survival rate for recipients of TCD-BM alone was
20% at day 40. All mice that received TCD-BM with
untreated BCD-SP were dead by day 20 (Figure 1E).
The addition of 1  107 irradiated SP seemed to
mitigate the rapid lethality of BCD-SP, with a survival
rate of 40% at day 40, but all recipients in this group
were dead at day 84 (Figure 1E). All mice that received
ﬂudarabine-treated BCD-SP survived beyond 100
days (Figure 1E), with a 	10% increase in body
weight, indicating normal growth (data not shown).
Analysis of day 42 blood samples demonstrated that
recipients of ﬂudarabine-treated BCD-SP had com-
plete donor chimerism, with normal levels of T and B
cells, chieﬂy derived from the donor BM (data not
shown). The data suggest that the reduced GVHD
potential of F-DLI (Figure 1A-C) was not attributable
to effects on the donor B-cell population or to co-
infusion of dead or apoptotic SP.
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Figure 1. Fludarabine treatment attenuates the GVHD potential of allogeneic donor lymphocytes while maintaining graft-facilitating effects.
B10.BR recipients underwent transplantation with C57BL/6 TCD-BM plus 0, 1, 3, 8, or 10 viable control DLI (A) or 1, 3, or 10  106 viable
F-DLI (B). Increasing thickness of lines indicates increasing numbers of DLI or F-DLI administered. Numbers within the graph indicate the
number of viable T cells transplanted over the total number of splenocytes transplanted. There were 20 mice per group, except groups
receiving no DLI (n  45), 8  106 control DLI (n  10), and 10  106 F-DLI (n  35). (C) Day 60 survival  weight scores for recipients
of TCD-BM plus untreated DLI or F-DLI. The number of viable T cells transplanted is shown on the x axis. (D) Peripheral blood analysis
for donor- and recipient-derived T-cell chimerism 60 days after transplantation. Error bars represent the SEM., Recipient T cells; o, donor
spleen T cells; , donor BM T cells. (E) Survival of B10.BR recipients transplanted with C57BL/6 TCD-BM plus 3.5  106 B cell–depleted
splenocytes containing 2.2  106 viable T cells that were ﬂudarabine cultured (2.2 Flud; upper solid line), cultured in media alone (2.2 Untr;
short dashes), or cultured in media and then added to 10  106 C57BL/6-irradiated (25 Gy) splenocytes (2.2 Untr  Irrard; irregular dashes).
There were 10 mice per experimental group, and 5 mice received TCD-BM only (0; regular dashes).
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Recipients of F-DLI Had Less GVHD
Histopathology and Lower Levels of Inflammatory
Serum Cytokines
We conﬁrmed that the survival advantage of F-
DLI was due to a reduction in GVHD by histologic
assessment of GVHD in transplant recipients. B10.BR
mice were transplanted with C57BL/6 TCD-BM
alone or combined with 3  106 untreated DLI, 10 
106 untreated DLI, or 10  106 F-DLI as in the
previous experiments. Three to 8 mice per group were
killed 14 to 16 days after transplantation, and tissues
were harvested for histopathologic assessment of
GVHD. Evidence of GVHD was consistently reduced
in recipients of F-DLI compared with either dose of
untreated DLI. Recipients of untreated DLI had
marked inﬁltration of lymphocytes in the liver peri-
portal regions (Figure 2A), whereas liver sections from
recipients of F-DLI retained a normal appearance
with minimal inﬁltration (Figure 2B). In recipients of
untreated DLI, numerous apoptotic cells were ob-
served in the intestinal epithelium (Figure 2C), par-
ticularly in the crypts, along with foci of epithelial
Figure 2. Histologic and serum cytokine parameters of GVHD progression are reduced among recipients of F-DLI. (A and B) Sections of liver
from B10.BR recipients of 10  106 untreated DLI or 10  106 F-DLI 16 days after transplantation. (A) Severe lymphocyte inﬁltration in the
liver periportal regions in the recipient of untreated DLI. (C and D) Transverse sections of intestinal crypt glands from recipients of untreated
DLI or F-DLI. (C) Granulation indicative of apoptotic cell death (arrows) in the recipient of untreated DLI. Original magniﬁcation, 400
for all images. (E) Day 16 histologic GVHD grade of liver and colon samples from mice that received TCD-BM alone (n  5) or combined
with 3  106 untreated DLI (n  4), 10  106 untreated DLI (n  8), or 10  106 F-DLI (n  3). (F) Day 16 serum levels of IFN- for the
same recipients shown in (E). Error bars represent the SEM.
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ulceration. All signs of intestinal GVHD were less
evident among recipients of F-DLI (Figure 2D). The
average day 14 to 16 histologic GVHD grades for
liver and colon are shown in Figure 2E on a scale of 0
to 4. Compared with the 10  106 untreated DLI
group, the F-DLI group had signiﬁcantly reduced
symptoms of GVHD in both liver (P .02) and colon
epithelial (P  .01) tissues. The reduced histologic
evidence of GVHD at day 14 to 16 among recipients
of F-DLI was accompanied by lower IFN- levels in
serum (versus the 3  106 untreated group, P  .02;
and the 10  106 untreated group, P  .01; Figure
2F). A similar trend was observed for serum levels of
TNF-, although the data were not statistically sig-
niﬁcant (data not shown).
F-DLI Have Superior GVL Activity without
Dose-Limiting GVHD
Transplantation of C57BL/6 TCD-BM into
B10.BR recipients with graded numbers of untreated
C57BL/6 donor SP (0, 1  106, 3  106, or 10  106)
on the day of BMT, or a total of 50  106 SP (in 5
weekly injections), resulted in 50%, 100%, 80%, 0%,
and 0% survival at 200 days after transplantation,
respectively (Figure 3, n  10 mice per group). Mice
that received more than 3  106 donor SP died of
GVHD on the basis of clinical and histologic staging
(data not shown). Transplantation with the same
numbers of F-DLI resulted in 50%, 100%, 100%,
80%, and 80% survival at day 200, demonstrating that
F-DLI is well tolerated in this transplant model over
a large dose range. To test the GVL activity of F-DLI,
a second series of BMT experiments was performed in
parallel, incorporating a transplanted lymphoblastic
lymphoma tumor cell line, LBRM [12]. Transplanta-
tion of TCD-BM alone into mice inoculated on day
1 with 3  106 LBRM (	10 times the LD50) led to
0% survival at 60 days after transplantation, demon-
strating the lethality of the transplanted tumor (Figure
3). The addition of graded doses of untreated donor
SP to recipients of supralethal doses of LBRM showed
GVL activity over a narrow dose range, with 70% and
40% day 200 survival among recipients of 1 106 and
3  106 donor SP, respectively, and 0% survival seen
with larger doses of untreated SP due to dose-limiting
GVHD. Transplantation of F-DLI in the LBRM
model resulted in a broader survival-versus-dose
curve, with day 200 survival rates of 80%, 90%, 70%,
and 60% for doses of 1, 3, 10, and 50  106 F-DLI,
respectively (Figure 3). Chimerism analyses of mice
surviving to day 30 showed a dose-dependent in-
crease in DLI-derived donor T cells, with recipients
of 50  106 viable F-DLI having 60% of T cells
derived from donor spleen versus recipients of the
same number of untreated DLI, in which only 30% of
blood T cells were derived from donor spleen (data
not shown). The day 200 survival and enhanced
immune reconstitution seen among recipients of F-
DLI support the hypothesis that ex vivo ﬂudarabine
treatment effectively separates GVL activity from
GVHD in an MHC-mismatched BMT model.
Fludarabine Treatment Did Not Reduce the
Alloreactive T-Cell Frequency, But Recipients
Engrafted with F-DLI Were Tolerant to
Host-Type Alloantigen
The immediate effect of ﬂudarabine exposure on
the frequency of alloreactive T cells was measured by
limiting-dilution analysis (LDA). The frequency of
ﬂudarabine-treated C57BL/6 T cells reactive to irra-
diated B10.BR SP (1/1000) was unchanged compared
with the frequency of alloreactive cells cultured in
media alone (1/910; Figure 4A). The results demon-
strate that the frequency of alloreactive T cells was not
directly affected by 24-hour ex vivo ﬂudarabine treat-
ment. Furthermore, donor-derived T cells recovered
from stably engrafted, fully chimeric B10.BR recipi-
ents of C57BL/6 TCD-BM plus F-DLI were tolerant
to host-type (B10.BR) and donor-type (C57BL/6)
stimulators in a 1-way mixed lymphocyte reaction
(MLR) but retained proliferative activity against a
DBA/2 (H-2d) third-party stimulator (Figure 4B), in-
dicating that prior ﬂudarabine exposure had not pro-
duced a global effect on the proliferative responses of
Figure 3. F-DLI retain GVL activity. Survival of B10.BR mice
transplanted with C57BL/6 TCD-BM and untreated (open sym-
bols) or ﬂudarabine-treated (ﬁlled symbols) splenocytes from
C57BL/6 donors. Groups of 10 mice received 11 Gy of radiation on
day 2 and TCD-BM on day 0, and then they received single
infusions of 0, 1, 3, or 10  106 donor splenocytes on day 0 or 5
weekly infusions of 10  106 donor splenocytes. For groups receiv-
ing LBRM, 3  106 cells were administered on day 1. E, un-
treated DLI; F, FDLI; , untreated DLI  LBRM; , F-DLI 
LBRM. Overlapping data points are offset for clarity. Note that
symbols on the y axis (x  0) represent groups that received
TCD-BM without added splenocytes.
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donor-derived T cells. Recipients of TCD-BM alone
had graft rejection with autologous reconstitution;
hence, the recipients’ T cells remained nonreactive to
host antigen and reactive to donor and third-party
alloantigen. Results were similar to those obtained
with wild-type B10.BR SP as responders (Figure 4B).
Equivalent data are not available for recipients of
untreated DLI because of 100% GVHD mortality.
Fludarabine-Treated Donor T Cells Retained
Proliferative Capacity In Vivo
The potential effect of ﬂudarabine exposure on
the short-term proliferation of allogeneic T cells in
vivo was examined by using CFSE dye tracking. The
proliferation of wild-type C57BL/6 (H-2b) T cells and
anti–H-2d transgenic 2CTCR T cells (C57BL/6 back-
ground [10]) was compared in BALB/c (H-2d) scid/
scid mice. The use of scid recipients allowed for a low
signal-to-noise ratio. C57BL/6 and 2CTCR SP were
combined in a 10:1 ratio before 24-hour culture in
standard or ﬂudarabine-containing medium and then
labeled with CFSE after the culture period. Recipient
mice were irradiated with 2.5 Gy, underwent trans-
plantation with 3  107 CFSE-labeled cells, and then
were killed after 40, 64, or 88 hours. Recipient SP
suspensions were analyzed by ﬂow cytometry; the
CFSE ﬂuorescence intensity of labeled donor cells was
decreased by half after each cell division (Figure 5A).
The percentage of C57BL/6 CD4 and CD8 T cells
undergoing 1 or more rounds of cell division was
determined at 40 and 64 hours after transplantation
[18] and is summarized in Table 2. Both untreated and
ﬂudarabine-treated C57BL/6 T cells proliferated
equally in the ﬁrst 4 days after transplantation in
BALB/c scid/scid mice, with approximately 30% of T
cells undergoing 1 to 8 cell divisions within the ﬁrst 64
hours after transplantation (Figure 5A; Table 2). Most
of the ﬂudarabine-treated and -untreated 2CTCR
CD8 allogeneic T cells had undergone 5 to 8 cell
divisions during the same time period (Figure 5A; note
that 2CTCR transgenic mice have very few CD4 T
cells). The fraction of dividing T cells could not be
accurately determined by using this method at the
88-hour time point, because most of the donor-de-
rived T cells had divided more than 8 times, with
CFSE intensity reduced to background levels (data
not shown). Of note, untreated and ﬂudarabine-
treated T cells showed no signiﬁcant difference in the
fraction of original cells that divided or in the number
of cell divisions measured by CFSE during the analysis
period. Similar CFSE proliferation proﬁles were ob-
tained from recipients of C57BL/6 3 B10.BR trans-
plants and recipients of C57BL/63 BALB/c scid/scid
transplants without added transgenic allospeciﬁc T
cells (data not shown). These results demonstrate that
ﬂudarabine treatment did not have a speciﬁc inhibi-
tory effect on homeostatic proliferation of allogeneic
donor T cells [19] or on allospeciﬁc CD8 transgenic
T cells.
To speciﬁcally examine the effect of ﬂudarabine
treatment on C57BL/6 alloreactive cell proliferation
in response to alloantigen exposure in vivo, CFSE-
labeled DLI or F-DLI cells were administered to
Figure 4. Effect of ﬂudarabine treatment on alloreactivity of T cells
in vitro. (A) LDA of frequency of alloreactive T cells in C57BL/63
B10.BR 1-way MLR. Open circle indicates untreated DLI; ﬁlled
square, F-DLI. The number of viable T cells plated per well is
shown. LDA was performed using C57BL/6 responder splenocytes
stimulated with irradiated B10.BR splenocytes. The frequencies of
alloreactive cells in untreated and ﬂudarabine-treated cultures are
shown. The data are representative of 3 individual experiments. See
Materials and Methods for details. (B) T cells from engrafted
recipients are tolerant to both recipient- and donor-type alloanti-
gens but retain reactivity to third-party–type antigen and mitogen.
Proliferative responses are shown for spleen cells harvested from
B10.BR mice 8 months after transplantation with C57BL/6
TCD-BM only or with C57BL/6 TCD-BM plus ﬂudarabine-
treated splenocytes. The proliferation of freshly isolated B10.BR
splenocytes was analyzed for comparison. Proliferation was mea-
sured after stimulation with irradiated splenocytes from C57BL/6
(H-2b) donor-type, B10.BR (H-2k) recipient type or DBA/2 (H-2d)
third-party mice or concanavalin A. A total of 400,000 responding
cells were cultured with 200,000 irradiated stimulators in a 7-day
MLR. Error bars represent SD of 8 replicate wells.
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unirradiated F1(C57BL/6  B10.BR) recipients. In
the parent3 unirradiated F1 system, only alloreactive
donor cells proliferate [18], in contrast to the combi-
nation of alloreactive and homeostatic proliferation
observed in irradiated allogeneic recipients [19]. Anal-
ysis of early donor T-cell proliferation in the spleens
of recipient animals 48 hours after transplantation
demonstrated similar frequencies of dividing cells
among untreated (average, 12%) and ﬂudarabine-
treated T cells (average, 7%; Figure 5B). At 72 hours,
the dividing cell frequency was 7% for both untreated
and ﬂudarabine-treated T cells. Concurrent analysis
of CFSE proliferation proﬁles and CD69 expression,
as an indicator of early alloactivation, demonstrated
upregulation of CD69 on both untreated and ﬂudara-
bine-treated CD4 donor T cells 24 hours after trans-
plantation, early division of CD69 T cells at 48
hours, and reduced CD69 expression among divided
cells at 72 hours after transplantation (Figure 5B). The
data suggest that ﬂudarabine pre-exposure does not
inhibit early proliferation of alloreactive donor T cells
in response to alloantigen in vivo.
Fludarabine Pre-Exposure Did Not Affect
Long-term Donor T-Cell Proliferation In Vivo
Additional experiments were conducted to quan-
tify donor-derived lymphocyte populations in alloge-
neic recipient spleens at time points up to 36 days after
transplantation (when recipients of untreated DLI
showed signiﬁcant GVHD symptoms). B10.BR recip-
ients underwent transplantation with 1  106
C57BL/6 (CD45.1) TCD-BM and 1  107 untreated
C57BL/6 (CD45.2) DLI or F-DLI. Three to 8 recip-
ients per group were killed at 2, 6, 10, 15, 21, and 36
days after transplantation. Total SP counts and ﬂow
cytometry analyses allowed determination of the num-
bers of T and B cells derived from donor BM (H-2b
and CD45.1), donor SP (H-2b and CD45.2), and
B10.BR recipients (H-2k and CD45.2). T cells from
untreated DLI or F-DLI showed similar cell numbers
and proliferation rates, with a peak of 200-fold CD8
cell expansion at day 15, followed by a gradual reduc-
tion in cell number (Figure 5C). CD4 cells expanded
50-fold by day 15 (Figure 5C). The number of F-
DLI–derived T cells in recipient spleens averaged
70% of that found in recipients of untreated DLI for
2 to 21 days after transplantation, and no signiﬁcant
difference was found at any time point. In contrast,
the number of F-DLI–derived B cells at 2 days after
transplantation was only 12% of that from untreated
DLI and increased to 32% at 15 days after transplan-
tation (Figure 5D). At day 36, the proliferation of
F-DLI–derived B cells in recipient spleens surpassed
that for recipients of untreated DLI.
Fludarabine Exposure Led to Loss of
CD4CD44low Cells
We tested whether there were subsets of activated,
naı¨ve, or memory T cells that were more sensitive to
ﬂudarabine and that might have contributed to the
altered immunoreactivity observed with F-DLI.
B10.BR recipient mice underwent transplantation
with 3 106 untreated or ﬂudarabine-treated puriﬁed
C57BL/6 Thy1.1 T cells. Mice were killed on day 2
after transplantation, and SP were analyzed for the
expression of Thy1.1 (donor T-cell marker), CD4,
CD8, and CD25, CD44, CD62L, or CD122. The
most notable difference between donor T cells recov-
ered from recipients of ﬂudarabine-treated or -un-
treated T cells was the relative lack of the
CD4CD44low-naive T-cell population in recipients
of ﬂudarabine-treated T cells (Figure 6A). A reduction
in CD4CD62Lhigh T cells was also observed, con-
sistent with a loss of CD4-naive T cells (Figure 6A).
Because there are no signiﬁcant differences in the
absolute numbers of donor CD4 and CD8 T cells in
spleens of F-DLI versus untreated DLI recipients at
2 days after transplantation (Figure 5C), the T-cell
subset proﬁles presented here may be considered rep-
resentative of donor T-cell populations found in vivo
after allogeneic transplantation. In a separate exper-
iment, T cells were cultured in the presence or
absence of ﬂudarabine for 24 hours and then washed
and placed in fresh media. Fludarabine did not alter
the relative representation of CD4CD44low or
CD4CD44high cells after the initial 24-hour cul-
ture, but after an additional 1 to 2 days of culture in
the absence of ﬂudarabine, the CD4CD44low pop-
ulation was markedly reduced (Figure 6B), thus cor-
roborating the in vivo ﬁndings.
Additional experiments to investigate the immu-
noregulatory roles of untreated and ﬂudarabine-
treated CD4CD44high versus CD44low cells used in-
tracellular cytokine analysis to determine the potential
for these populations to produce IL-2, TNF-,
IFN-, and IL-10 in vitro (Figure 6C). As described
previously, SP were incubated with or without ﬂu-
darabine for 24 hours and then were washed and
placed in fresh media overnight before 5 hours of
stimulation with PMA/ionomycin. Cytokine produc-
tion analysis of CD4 T cells is shown in Figure 6C.
Striking differences in the levels of IL-2 and TNF-
production were observed. In the untreated cultures,
both CD4CD44low and CD4CD44high T cells pro-
duced these cytokines, and because CD4CD44low
cells were eliminated or apoptotic in the ﬂudarabine-
treated culture, IL-2 and TNF- production were not
observed for this population. Fludarabine-treated
CD4CD44high cells continued to produce these cy-
tokines. Note that CD4CD44high cells produced IL-
10, whereas CD44low cells did not. Hence, the ﬂu-
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darabine-treated culture contained proportionally
more IL-10–producing CD4 cells (8%) than the un-
treated culture (4%). A similar trend was observed for
IFN-–producing cells. Although the cytokine pro-
duction capability may differ in the transplant setting
versus PMA/ionomycin stimulation, these results sug-
gest a skewing of the T-cell population from a Th-1 to
a Th-2 phenotype in the ﬂudarabine-treated culture.
The representation of CD4CD44CD25 cells af-
ter untreated or ﬂudarabine-treated culture was also
examined (Figure 6C). In the untreated culture,
approximately 60% of CD4 cells were CD44low,
32% were CD44highCD25, and 6% were
CD44highCD25. In the ﬂudarabine-treated culture,
only 34% of CD4 T cells were CD44low, whereas
52% were CD44highCD25 and 11% were
CD44highCD25. Thus, the ﬂudarabine-treated cul-
ture had a slightly larger representation of
CD4CD25 T cells, a population that may include
activated T cells and regulatory T cells [20].
DISCUSSION
Multiple strategies of BMT engineering that in-
volve depletion of T cells from the graft have reduced
the incidence of GVHD, but because of higher rates
of infection and relapse, they have not resulted in
signiﬁcant improvements in survival outcomes [21].
Several approaches to reduce the GVHD activity of
allogeneic donor T cells while preserving the contri-
bution of donor T cells to immune reconstitution have
been investigated: thymidine kinase (TK) transduc-
tion [22-24]; removal of alloreactive CD25 or
CD69 T cells after MLR [25]; ex vivo tolerance by
using monoclonal antibodies or soluble receptors that
block the second signals necessary for T-cell activa-
tion [26,27]; in vitro exposure to IL-2 and anti-CD3 as
a nonspeciﬁc method to generate activated, but non-
alloreactive, donor T cells [28]; “cytokine starvation”
in mixed lymphocyte cultures with third-party alloge-
neic stimulators [29]; and elimination of alloactivated
T cells from MLR by incubation with 4,5-dibromo-
rhodamine 123 and exposure to light [30]. We have
previously described ex vivo treatment of donor T
cells with radiation so that their proliferative capacity
in vivo is impaired to the extent that they are not
capable of producing GVHD [1]. Ex vivo exposure of
T cells to psoralen and UV-A light nonspeciﬁcally
blocks the proliferative capacity of T cells in vivo
[31,32], whereas treatment with leucyl-leucine methyl
ester inactivates perforin activity in CD8T cells [33].
These approaches are based on nonspeciﬁc T-cell
inactivation or deletion/tolerance of alloreactive T-
cell subsets. The relative advantage of one method of
reducing donor T-cell alloreactivity versus another
remains to be determined. Clinical studies to date
have not demonstrated the clear superiority of any
approach because of limited GVL activity of TK-
transduced [23] or irradiated [34] donor T cells and
the persistence of alloreactivity after ex vivo co-stim-
ulatory blockade [26]. This study describes a novel
approach, ex vivo ﬂudarabine pretreatment of alloge-
neic T cells, that seems to act by targeting a GVHD-
promoting CD4 T-cell subset while preserving the
overall ability of treated T cells to proliferate and
contribute to posttransplantation immunity.
The fully MHC-mismatched C57BL/63 B10.BR
model is more clinically relevant than transplantation
systems that use minor histocompatibility antigen
strains because compared with mice, humans have a
higher propensity for developing GVHD when they
are administered low numbers of allogeneic T cells.
Using the C57BL/63 B10.BR model, we have shown
that ex vivo ﬂudarabine treatment speciﬁcally reduced
the GVHD potential of allogeneic lymphocytes,
thereby improving the therapeutic index of DLI (Fig-
ure 1C and D). This ﬁnding is consistent with analyses
of histologic and serum cytokine manifestations of
GVHD: recipients of 3  106 and 10  106 DLI had
similar levels of these GVHD symptoms, whereas
recipients of 10  106 F-DLI had reduced levels of
liver and colon GVHD pathology and inﬂammatory
serum cytokines (Figure 2). The data support the
hypothesis that ﬂudarabine pretreatment speciﬁcally
reduces the GVHD potential of allogeneic T cells and
that reduced GVHD activity is not attributable to a
simple reduction in the number of allogeneic T cells
administered. It is important to note that transplant
experiments incorporating the LBRM leukemic cell
line show that allogeneic F-DLI retain enough type 1
immune activity to mediate GVL activity against the
transplanted lymphoma with low GVHD mortality
‹
Figure 5. F-DLI T cells proliferate in MHC-mismatched recipient spleen. (A) CFSE proliferation proﬁles of untreated or ﬂudarabine-
treated wild-type C57BL/6 H-2b and 2CTCR transgenic donor T cells recovered from spleens of BALB/c scid/scid H-2d recipients 40 and
64 hours after transplantation. Top 2 rows show wild-type (WT) CD4 T cells. Middle 2 rows showWT CD8 T cells. Bottom 2 rows show
2CTCR transgenic CD8 T cells. (B) CFSE proliferation proﬁles and CD69 expression of CD4C57BL6 T cells in unirradiated F1
(C57BL/6  B10.BR) recipients at 24, 48, and 72 hours after transplantation. (Top) Untreated donor-derived CD4 T cells. (Bottom)
Fludarabine-treated donor-derived CD4 T cells. (C) Expansion of untreated (open symbols) and ﬂudarabine-treated (ﬁlled symbols)
C57BL/6 donor T cells in B10.BR recipient spleens. (D) Expansion of untreated and ﬂudarabine-treated C57BL/6 donor B cells in B10.BR
recipient spleens. Total splenocyte counts were multiplied by the fraction of donor splenocyte-derived CD4, CD8, and CD19 cells as
determined by ﬂow cytometric analyses. Three to 8 recipients per group were analyzed at each time point. Error bars represent the SEM.
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over a broad DLI dose range and with a therapeutic
index clearly superior to that of untreated DLI (Figure
3). Additional studies indicate that F-DLI contributes
to posttransplantation immunity against the murine
cytomegalovirus in allogeneic recipients without caus-
ing signiﬁcant GVHD (E.K.W., unpublished data).
Our initial hypothesis for the reduced GVHD
activity of ﬂudarabine-treated allogeneic T cells was
limited long-term survival of alloreactive donor T
cells in vivo, similar to the effect of irradiation [1] or
psoralen treatment [32]. Surprisingly, ﬂudarabine-
treated donor T cells expanded and persisted in recip-
ient spleens at levels indistinguishable from untreated
donor T cells (Figure 5). Further analyses of donor
T-cell subsets showed that ﬂudarabine pretreatment
reduced the CD4CD44low population both in allo-
geneic recipient spleens and in vitro (Figure 6A and
B). Fludarabine exposure increased the relative num-
bers of CD4CD44high memory-type donor cells that
are associated with predominance of Th-2 immune
responses [35,36]. Speciﬁcally, CD4 T cells that re-
mained viable after ﬂudarabine treatment produced
proportionally less IL-2 and TNF- (Th-1 cytokines)
and more IL-10 (a Th-2 cytokine) when stimulated in
vitro with PMA/ionomycin (Figure 6C). The in-
creased numbers of CD4 T cells with a Th-2 pheno-
type may explain, in part, the reduced acute GVHD
activity observed after ﬂudarabine treatment [37]. A
concurrent modest enrichment of the CD4CD25
population was also observed (Figure 6C). Of note,
CD4CD25 T cells include activated as well as reg-
ulatory populations [20]. The ﬁnding that the immu-
nosuppressive effect of ﬂudarabine was more pro-
nounced on naive T cells than on memory T cells is
consistent with results obtained in membranous ne-
phropathy patients treated with ﬂudarabine [38]. A
similar reduction in CD4CD44low T cells was ob-
served by Kishimoto and Sprent [39] after murine T
cells were cultured overnight with plate-bound anti-
T-cell receptor monoclonal antibodies. The authors
showed that CD4CD44low cells were susceptible to
Fas-mediated apoptosis triggered by T-cell receptor
engagement. Desbarats et al. [40] also showed that
CD4CD44low-naive murine T cells died as a result
of simultaneous exposure to anti-CD3 antibody and
Fas ligation, whereas CD4CD44high memory T cells
were stimulated to proliferate under the same condi-
tions, and Hartwig et al. [41] showed that in vitro
Fas-mediated activation-induced cell death eliminated
alloreactive T cells and prevented GVHD in alloge-
neic recipients. Although our data bear some interest-
ing similarities to these studies, and in vitro exposure
to ﬂudarabine has been shown to increase FasL ex-
pression and Fas messenger RNA levels in leukemic
cell lines [42,43], preliminary experiments of Fas ex-
pression on ﬂudarabine-treated SP in vitro failed to
show upregulation on CD4-naive T cells, militating
against involvement of this mechanism as responsible
for the speciﬁc sensitivity of CD4CD44low T cells to
ﬂudarabine-induced apoptosis (Giver et al., unpub-
lished data).
Because the role of CD4CD44high donor T cells
in the initiation of GVHD has been described [44],
it may seem paradoxical that a reduction in
CD4CD44low donor T cells reduces GVHD activity.
Our results suggest that CD4CD44low-naive donor
T cells contribute to the Th-1 inﬂammatory response
Table 2. Percentage of C57BL/6 T Cells Proliferating in BALB/c
scid/scid Recipient Spleen*
Hours after
Transplantation CD4 CD8
Untreated
DLI
Fludarabine
DLI
Untreated
DLI
Fludarabine
DLI
40 8% 7% 10% 6%
64 23% 29% 30% 32%
*The percentage of donor T cells proliferating in allogeneic recip-
ient spleen was determined by the method of Suchin et al. [18].
Brieﬂy, the numbers of undivided cells (Pundiv) and those pro-
duced through 1 to 8 rounds of cell division were obtained from
the CFSE staining proﬁle. The calculated number of precursor
cells necessary to account for all the divided cells is Pdiv. Hence,
the total number of precursors (Ptot) is Pdiv  Pundiv, and the
percentage of precursors undergoing division is determined as
Pdiv/Ptot. The data represent the mean of 2 individual experi-
ments.
‹
Figure 6. Fludarabine treatment reduced the CD4CD44low donor T-cell population after transplantation or additional culture time and
altered the cytokine production proﬁle of donor CD4 cells. (A) CD25, CD44, CD62L, and CD122 expression proﬁles are shown for C57BL/6
donor CD4 (top) and CD8 (bottom) T cells recovered from B10.BR recipient spleen 40 hours after transplantation. Histograms representing
untreated donor T cells are shown by a thin line and gray ﬁll, and histograms representing ﬂudarabine-treated donor T cells are shown by
a thick line without ﬁll. Results are representative of 2 individual experiments. U- and F- indicate the percentage of events in the right-hand
gate for recipients of untreated and ﬂudarabine-treated T-cells, respectively. Gates were set to discriminate CD4 or CD8 T cells with the
highest level of expression for the various activation markers on the basis of the separation of these populations among untreated
donor-derived T cells. (B) The pattern of CD44 expression for CD4 T cells cultured 24 hours with ﬂudarabine (heavy black line) or media
alone (gray ﬁlled area) and then washed and cultured in fresh media without ﬂudarabine for 40 or 64 hours. Histograms represent CD44
expression for the population of CD4 T cells surviving at the time of sampling, demonstrating the differential survival of CD44low and
CD44high cells. U- and F- indicate the percentage of viable CD4CD44 cells among untreated and ﬂudarabine-treated CD4 cells,
respectively. (C) Cytokine production and CD44/CD25 proﬁles of CD4 T cells in PMA/ionomycin-stimulated cultures of untreated or
ﬂudarabine-treated splenocytes. Results are representative of those obtained with splenocytes from 5 individual C57BL/6 mice.
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in the allogeneic recipient and show that reduction of
this cell type by using ﬂudarabine pretreatment results
in reduced GVHD morbidity and mortality without
altering the overall proliferation, engraftment, and
GVL activity of allogeneic donor T cells. We have not
determined whether any potential functional alter-
ation of the remaining CD4CD44low T cells that
survive 40 to 64 hours after ﬂudarabine treatment
(Figure 6B) contributes to reduced GVHD capacity.
The reduction in viable CD4CD44low donor T cells
may lessen the incidence and severity of chronic
GVHD, because naive CD44low T cells represent one
of the major contributors to posttransplantation ho-
meostatic proliferation after adoptive transfer [45].
However, CFSE labeling studies showed that initial
proliferation of CD4 donor T cells from F-DLI was
not signiﬁcantly different from proliferation of un-
treated donor CD4 T cells in spleens of recipients
treated with ablative doses of radiation (Figure 5A),
conditions in which homeostatic proliferation of T
cells will predominate [19]. Recent reports emphasize
that donor T-cell proliferation in allogeneic recipient
spleen does not necessarily correspond to GVHD
progression in target organs and focus on donor T-
cell activity and inﬂammatory responses in the intes-
tinal tissues as critical events in GVHD progression
[44,46,47]. Our data also show that ﬂudarabine pre-
treatment did not alter early donor T-cell prolifera-
tion in a parental 3 nonirradiated F1 transplant
model (Figure 5B), in which donor T-cell prolifera-
tion is limited to alloreactive clones that recognize the
nonshared haplotype [18]. The data are consistent
with in vitro LDA studies showing that the frequency
of alloreactive cells is not affected by ﬂudarabine pre-
treatment (Figure 4A).
Other potential factors that could have contrib-
uted to the reduced GVHD activity of F-DLI, includ-
ing the presence of dead cells in the treated cell prep-
aration [17] and the relative reduction in B cells
compared with untreated DLI [16], were examined.
However, neither the use of BCD-SP nor the coad-
ministration of T cells with irradiated SP resulted in
reduced GVHD mortality (Figure 1E). The key effect
of ﬂudarabine exposure seems to be the selective loss
of the CD4CD44low population that occurred in
vitro in cultures of puriﬁed T cells in the absence of
any interaction with alloantigen or antigen presenting
cells (Figure 6B), and in vivo after transfer of F-DLI
into allogeneic recipients (Figure 6A). This is sup-
ported by additional C57BL/6 3 B10.BR BMT ex-
periments with ﬂuorescence-activated cell sorter–pu-
riﬁed T-cell subsets. Recipients of 1  106 CD8 plus
2 106 CD4CD44high T cells have a 90% day100
survival rate, normal weight gain, and full donor-
derived T-cell chimerism. In contrast, all recipients of
TCD-BM plus 1  106 CD8 and 2  106 total
CD4 T cells (containing 1.7  106 CD4CD44low
and 0.3  106 CD4CD44high) die rapidly because
of acute GVHD (Giver and Waller, unpublished
data). A recent publication by Anderson et al. [48]
demonstrates that memory CD4 T-cells do not
induce GvHD in a MiHA-incompatible murine
transplant system, and similar results have been
reported by Chen et al. [49], who used allogeneic
transfer of CD3 naive T-cells (rapid GvHD) ver-
sus CD3 memory T-cells (high survival rate).
These data further support our hypothesis that ﬂu-
darabine-induced reduction of donor naive CD4
T-cells, while sparing memory CD4 T-cells, re-
duces the GvHD potential of allogeneic DLI.
Whereas physical separation of donor T-cell subsets
is expensive and time consuming, ﬂudarabine pre-
treatment is simple and relatively inexpensive. This
method for selective depletion of the
CD4CD44low donor cell population from alloge-
neic DLI represents an interesting and potentially
clinically relevant approach for limiting GVHD
while preserving immune reconstitution, graft-
facilitating effects, and GVL activity of allogeneic
donor T cells.
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